Kringle Pharma, Inc. (JP:4884)
:4884
Want to see JP:4884 full AI Analyst Report?
4884 Stock Chart & Stats
¥379.00
-¥48.00(-4.72%)
At close: 4:00 PM EST
¥379.00
-¥48.00(-4.72%)
Day’s Range― - ―
52-Week Range¥287.00 - ¥917.00
Previous CloseN/A
Volume217.60K
Average Volume (3M)51.60K
Market Cap
¥2.77B
Enterprise Value¥1.48B
Total Cash (Recent Filing)¥1.62B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-133.99
Shares Outstanding8,383,200
10 Day Avg. Volume53,170
30 Day Avg. Volume51,600
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)2.41
Price to Sales (P/S)43.77
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary HGF Platform And Focused PipelineKringle’s proprietary HGF technology and pipeline focus create a durable competitive advantage in regenerative and neurodegenerative therapeutics. Owning core biology reduces dependence on third-party platforms, supports differentiated assets for partnerships, and underpins long-term value if clinical progress validates mechanism.
Low Financial Leverage / No Reported DebtA no-debt capital structure materially reduces bankruptcy and refinancing risk for a cash-burning biotech. Low leverage preserves optionality to raise equity or strike licensing/collaboration deals without immediate debt servicing, extending runway and enabling strategic flexibility over the medium term.
Diverse Non-dilutive Funding And Some Revenue GenerationReliance on grants, partnerships and licensing provides multiple funding channels beyond pure product sales. Milestones and royalties can supply intermittent non-dilutive cash and validate asset value, supporting development continuity and de-risking financing needs relative to firms solely dependent on equity raises.
Bears Say
Ongoing Cash Burn And Weak Cash GenerationConsistently negative operating cash flows indicate structural cash burn, forcing repeated external funding or dilutive financing. Over a 2–6 month horizon this weak cash-generation profile limits strategic options, increases funding risk, and can pressure R&D pacing or partnership terms if milestones require cash.
Structural Unprofitability And Steep Recent Revenue DeclineDeep, persistent losses and a sharp top-line drop (≈31% in 2025) signal weak commercial traction and unsustainable margins absent major clinical or licensing wins. This trend undermines internal funding capacity, increases reliance on partners/markets, and raises execution risk for advancing late-stage development.
Small Scale And Inconsistent Commercial BaseA small commercial footprint (15 employees) plus volatile, shrinking revenues means limited internal capacity to commercialize or scale programs independently. This structural constraint increases dependency on external partners for trials, manufacturing, and market access, slowing growth and creating execution bottlenecks.
Kringle Pharma, Inc. News
4884 FAQ
What was Kringle Pharma, Inc.’s price range in the past 12 months?
Kringle Pharma, Inc. lowest stock price was ¥287.00 and its highest was ¥917.00 in the past 12 months.
What is Kringle Pharma, Inc.’s market cap?
Kringle Pharma, Inc.’s market cap is ¥2.77B.
When is Kringle Pharma, Inc.’s upcoming earnings report date?
Kringle Pharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 48 days.
How were Kringle Pharma, Inc.’s earnings last quarter?
Kringle Pharma, Inc. released its earnings results on May 11, 2026. The company reported -¥43.17 earnings per share for the quarter, missing the consensus estimate of N/A by -¥43.17.
Is Kringle Pharma, Inc. overvalued?
According to Wall Street analysts Kringle Pharma, Inc.’s price is currently Overvalued.
Does Kringle Pharma, Inc. pay dividends?
Kringle Pharma, Inc. does not currently pay dividends.
What is Kringle Pharma, Inc.’s EPS estimate?
Kringle Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kringle Pharma, Inc. have?
Kringle Pharma, Inc. has 8,383,200 shares outstanding.
What happened to Kringle Pharma, Inc.’s price movement after its last earnings report?
Kringle Pharma, Inc. reported an EPS of -¥43.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.085%.
Which hedge fund is a major shareholder of Kringle Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4884
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kringle Pharma, Inc.
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Technical Analysis
Peptidream
―
NanoCarrier Co., Ltd.
―
Ribomic, Inc.
―
Delta-Fly Pharma, Inc.
―
FunPep Company Limited
―